S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30

Amyris Stock Forecast, Price & News

+0.42 (+10.07%)
(As of 01/24/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
9.63 million shs
Average Volume
7.45 million shs
Market Capitalization
$1.41 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive AMRS News and Ratings via Email

Sign-up to receive the latest news and ratings for Amyris and its competitors with MarketBeat's FREE daily newsletter.

Amyris logo

About Amyris

Amyris, Inc. engages in the provision of bioscience solutions. It offers its products to health and wellness, clean beauty, and flavor and fragrance markets. The company was founded by Jack D. Newman, Kinkead Keith Reiling, and Neil Renninger on July 17, 2003 and is headquartered in Emeryville, CA.


Amyris (NASDAQ:AMRS) Shares Up 6%
January 24, 2022 |  americanbankingnews.com
Amyris (NASDAQ:AMRS) Sets New 52-Week Low at $4.32
January 21, 2022 |  americanbankingnews.com
3 New ETFs to Put on Your January Buy List - InvestorPlace
January 19, 2022 |  investorplace.com
See More Headlines

Industry, Sector and Symbol

Industrial organic chemicals
Oil & Gas Refining & Marketing
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$173.14 million
Book Value
($0.72) per share


Net Income
$-331.04 million
Net Margins
Pretax Margin




Free Float
Market Cap
$1.41 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Social Links


Overall MarketRank

2.24 out of 5 stars

Basic Materials Sector

93rd out of 223 stocks

Industrial Organic Chemicals Industry

10th out of 23 stocks

Analyst Opinion: 3.5Community Rank: 3.7Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -

Amyris (NASDAQ:AMRS) Frequently Asked Questions

Is Amyris a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Amyris stock.
View analyst ratings for Amyris
or view top-rated stocks.

How has Amyris' stock been impacted by COVID-19 (Coronavirus)?

Amyris' stock was trading at $2.96 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AMRS stock has increased by 55.1% and is now trading at $4.59.
View which stocks have been most impacted by COVID-19

When is Amyris' next earnings date?

Amyris is scheduled to release its next quarterly earnings announcement on Tuesday, March 1st 2022.
View our earnings forecast for Amyris

How were Amyris' earnings last quarter?

Amyris, Inc. (NASDAQ:AMRS) announced its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.15) by $0.04. The biotechnology company had revenue of $47.90 million for the quarter, compared to analyst estimates of $64.21 million. Amyris's revenue for the quarter was up 39.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.41) EPS.
View Amyris' earnings history

When did Amyris' stock split? How did Amyris' stock split work?

Shares of Amyris reverse split on Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split.

What guidance has Amyris issued on next quarter's earnings?

Amyris updated its FY 2021 earnings guidance on Monday, December, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $330 million-$370 million.

What price target have analysts set for AMRS?

4 Wall Street analysts have issued 1 year price targets for Amyris' shares. Their forecasts range from $15.00 to $30.00. On average, they expect Amyris' share price to reach $22.00 in the next year. This suggests a possible upside of 379.3% from the stock's current price.
View analysts' price targets for Amyris
or view top-rated stocks among Wall Street analysts.

Who are Amyris' key executives?

Amyris' management team includes the following people:
  • John G. Melo, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Eduardo Alvarez, Chief Operating Officer (LinkedIn Profile)
  • Han Kieftenbeld, Chief Financial & Administration Officer
  • Sunil Chandran, Senior Vice President-Research & Development
  • Charles Kraft, SVP-Global Manufacturing & Process Development

What is John Melo's approval rating as Amyris' CEO?

53 employees have rated Amyris CEO John Melo on Glassdoor.com. John Melo has an approval rating of 54% among Amyris' employees. This puts John Melo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amyris own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Nokia (NOK), Gevo (GEVO), Inovio Pharmaceuticals (INO), Pfizer (PFE), AT&T (T), Dynavax Technologies (DVAX), Novavax (NVAX) and NVIDIA (NVDA).

What is Amyris' stock symbol?

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

Who are Amyris' major shareholders?

Amyris' stock is owned by a variety of institutional and retail investors. Top institutional investors include Nordea Investment Management AB (0.32%), Golden Green Inc. (0.01%), Avantax Advisory Services Inc. (0.01%), Sheets Smith Wealth Management (0.01%), Kestra Private Wealth Services LLC (0.01%) and Lattice Capital Management LLC (0.00%). Company insiders that own Amyris stock include Anthony Hughes, Eduardo Alvarez, Frank Kung, Hermanus Kieftenbeld, James F Mccann, John Melo, L John Doerr and Nicole Kelsey.
View institutional ownership trends for Amyris

Which institutional investors are selling Amyris stock?

AMRS stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP, and Sabal Trust CO. Company insiders that have sold Amyris company stock in the last year include Anthony Hughes, Eduardo Alvarez, Frank Kung, Hermanus Kieftenbeld, John Melo, and Nicole Kelsey.
View insider buying and selling activity for Amyris
or view top insider-selling stocks.

Which institutional investors are buying Amyris stock?

AMRS stock was purchased by a variety of institutional investors in the last quarter, including Nordea Investment Management AB, Avantax Advisory Services Inc., Golden Green Inc., Kestra Private Wealth Services LLC, Lattice Capital Management LLC, Sheets Smith Wealth Management, MJP Associates Inc. ADV, and Endurance Wealth Management Inc.. Company insiders that have bought Amyris stock in the last two years include Frank Kung, James F Mccann, and L John Doerr.
View insider buying and selling activity for Amyris
or or view top insider-buying stocks.

How do I buy shares of Amyris?

Shares of AMRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amyris' stock price today?

One share of AMRS stock can currently be purchased for approximately $4.59.

How much money does Amyris make?

Amyris has a market capitalization of $1.41 billion and generates $173.14 million in revenue each year. The biotechnology company earns $-331.04 million in net income (profit) each year or ($1.95) on an earnings per share basis.

How many employees does Amyris have?

Amyris employs 595 workers across the globe.

When was Amyris founded?

Amyris was founded in 2003.

What is Amyris' official website?

The official website for Amyris is amyris.com.

Where are Amyris' headquarters?

How can I contact Amyris?

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at (510) 450-0761, via email at [email protected], or via fax at 510-225-2645.

This page was last updated on 1/25/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.